top of page

Unlocking new Aptamer therapeutics with Generative AI

Learn more about PentaBind

Targeting of Any Protein

We design therapeutic drugs to target previously 'Undruggable' human proteins; the largest class of human proteins and a driver of multiple cancers and diseases

 

Our proprietary AI-based platform applies a powerful Generative AI approach to rapidly design aptamers (short, single-stranded RNA or DNA sequences) that have a higher performance when compared to aptamers developed in physical laboratory experiments such as SELEX.
 

Leveraging recent breakthroughs in mRNA vaccine development and antisense drugs, we design oligo drugs with a novel moeity: protein binding

WHO WE ARE

A Platform TechBio Company

PentaBind is a platform TechBio company consisting of bioinformaticians, data scientists, biophysicists, engineers and synthetic biology experts, who's CEO is a serial entrepreneur (1x biotech exit). They are backed by the prolific venture capital firm, Entrepreneur First and supported by Panacea Stars and P4SY.

vis_fig.png

PentaBind

Generative Algorithms and Aptamers will unlock the next generation of therapeutics

GET IN TOUCH

Contact us for partnership or investment enquiries, and job opportunities

  • LinkedIn
London City
Subscribe

Subscribe To Our Mailing List

Thanks for submitting!

bottom of page